Document Detail


Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib.
MedLine Citation:
PMID:  18274784     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: The multikinase inhibitor sunitinib has enhanced the treatment of renal cell carcinoma and gastrointestinal stromal tumor through an improved clinical response with decreased systemic toxicities. However, sunitinib is frequently associated with dermatological adverse reactions. The physical and psychosocial impact of frequent dermatological toxicities can affect consistent antineoplastic therapy and quality of life. PATIENTS AND METHODS: Dermatological adverse reaction information was compiled from Pfizer Medical Information and from abstracts from the 2007 American Society of Clinical Oncology annual meeting, Prostate Cancer Symposium, and Gastrointestinal Cancers Symposium. Published clinical trials of sunitinib in MEDLINE, Cochrane Library, Cochrane Controlled Trials Register, and EMBASE Drugs and Pharmacology databases were also included. Information was accessed on or before June 30, 2007. RESULTS: In the pooled analysis, all-grade hand-foot skin reaction occurred in 19% of patients (5% grades 3-4), skin discoloration in 28% (0% grades 3-4), dry skin in 16% (1% grades 3-4), skin rash in 13% (1% grades 3-4), dermatitis in 8% (2% grades 3-4), hair color changes in 10% (0% grades 3-4), alopecia in 6% (0% grades 3-4), and phototoxicity in <0.1%. CONCLUSIONS: Dermatological reactions associated with sunitinib occur frequently. Evidence-based treatment recommendations are needed in order to maximize quality of life and optimize clinical outcome.
Authors:
S E Rosenbaum; S Wu; M A Newman; D P West; T Kuzel; M E Lacouture
Related Documents :
9611604 - Squamous cell carcinoma arising from a nonhealing wound and osteomyelitis treated with ...
3493044 - Evaluation of circulating malignant cells provides prognostic information in cutaneous ...
10940064 - Photodynamic therapy of cutaneous lymphoma using 5-aminolevulinic acid topical applicat...
12653924 - Long-term control of mycosis fungoides of the hands with topical bexarotene.
16501234 - Prognostic value of cytology, nuclear matrix protein 22 (nmp22) test, and urinary bladd...
1595834 - Extended resection for locally advanced colorectal carcinoma.
Publication Detail:
Type:  Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Review     Date:  2008-02-15
Journal Detail:
Title:  Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer     Volume:  16     ISSN:  0941-4355     ISO Abbreviation:  Support Care Cancer     Publication Date:  2008 Jun 
Date Detail:
Created Date:  2008-05-26     Completed Date:  2008-10-17     Revised Date:  2009-11-19    
Medline Journal Info:
Nlm Unique ID:  9302957     Medline TA:  Support Care Cancer     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  557-66     Citation Subset:  IM    
Affiliation:
Department of Dermatology, Northwestern University, Feinberg School of Medicine, 676 N. St. Clair St., Suite 1600, Chicago, IL 60611, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Angiogenesis Inhibitors / adverse effects*
Drug Eruptions / epidemiology,  etiology*,  prevention & control
Humans
Incidence
Indoles / adverse effects*
Protein-Tyrosine Kinases / antagonists & inhibitors*
Pyrroles / adverse effects*
Quality of Life
Chemical
Reg. No./Substance:
0/Angiogenesis Inhibitors; 0/Indoles; 0/Pyrroles; 0/sunitinib; EC 2.7.10.1/Protein-Tyrosine Kinases

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  A systematic review of physical activity in prostate cancer survivors: outcomes, prevalence, and det...
Next Document:  Use of patient-controlled analgesia for pain control in dying children.